Research programme: small molecule therapeutics - Covant Therapeutics
Latest Information Update: 09 May 2023
At a glance
- Originator Covant Therapeutics
- Class Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 05 Apr 2023 Early research in Unspecified in USA (unspecified route) (Covant Therapeutics pipeline, April 2023)